Page last updated: 2024-12-11

4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6787155
CHEMBL ID443772
SCHEMBL ID13008066
MeSH IDM0060640

Synonyms (14)

Synonym
maiq
CHEMBL443772
[(5-amino-4-methylisoquinolin-1-yl)methylideneamino]thiourea
59261-39-1
4-methyl-5-aminoisoquinoline thiosemicarbazone
hydrazinecarbothioamide, 2-((5-amino-4-methyl-1-isoquinolinyl)methylene)-
4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone
maiq 1
SCHEMBL13008066
[(5-amino-4-methyl-1-isoquinolinyl)methylideneamino]thiourea
bdbm81247
[(5-amino-4-methyl-1-isoquinolyl)methyleneamino]thiourea
1-[(5-azanyl-4-methyl-isoquinolin-1-yl)methylideneamino]thiourea
cid_3035508

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Each of three ribonucleoside diphosphate reductase inhibitors was used as a third drug in combination with selected antitumor platinum (Pt) agents and cyclophosphamide (CY) in the treatment of advanced L1210 leukemia in C57BL/6 x DBA/2 mice."( Schedule-dependency assessments of ribonucleoside diphosphate reductase inhibitors when used in combination with platinum compounds plus cyclophosphamide in the treatment of advanced L1210 leukemia.
Atkins, LM; Gale, GR; Meischen, SJ; Schwartz, P, 1979
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1150329Antitumor activity against mouse S180A cells allografted in CD-1 mouse assessed as average survival at maximum effective dose administered qd for 6 days (Rvb = 12.6 +/- 0.6 days)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID350249Cytotoxicity against human P-gp-negative KB-3-1 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID350248Cytotoxicity against human P-glycoprotein-expressing KBV1 cells after 72 hrs by MTT assay2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1150331Inhibition of ribonucleoside-diphosphate reductase in rat hepatoma cells relative to 5-hydroxy-2-formylpyridine thiosemicarbazone1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID350247Selectivity ratio of IC50 for human P-gp-negative KB-3-1 cells to human P-glycoprotein-expressing KBV1 cells2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
AID1150330Antitumor activity against mouse S180A cells allografted in CD-1 mouse assessed as average survival at maximum effective dose administered qd for 6 days relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID1150328Toxicity in CD-1 mouse allografted with mouse S180A cells assessed as change in body weight at at maximum effective dose administered qd for 6 days (Rvb = 18.2%)1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID1150327Antitumor activity against mouse S180A cells allografted in CD-1 mouse assessed as dose required for maximum increase in mouse survival administered qd for 6 days1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
AID1150332Inhibition of ribonucleoside-diphosphate reductase in rat hepatoma cells relative to 4-(m-amino)phenyl-2-formylpyridine thiosemicarbazone1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
Potential antitumor agents. 13. 4-Methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (69.57)18.7374
1990's5 (21.74)18.2507
2000's2 (8.70)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.84 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]